GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (UKEX:MRK) » Definitions » Cyclically Adjusted FCF per Share

Merck (UKEX:MRK) Cyclically Adjusted FCF per Share : ₴144.64 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Merck Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Merck's adjusted free cash flow per share for the three months ended in Mar. 2024 was ₴35.184. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₴144.64 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Merck's average Cyclically Adjusted FCF Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 6.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 5.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Merck was 15.30% per year. The lowest was -3.70% per year. And the median was 5.30% per year.

As of today (2024-05-24), Merck's current stock price is ₴4844.00. Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ₴144.64. Merck's Cyclically Adjusted Price-to-FCF of today is 33.49.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 14.33. And the median was 22.51.


Merck Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Merck's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted FCF per Share Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 131.59 135.32

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.87 128.51 149.22 135.32 144.64

Competitive Comparison of Merck's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted Price-to-FCF falls into.



Merck Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=35.184/131.7762*131.7762
=35.184

Current CPI (Mar. 2024) = 131.7762.

Merck Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 27.411 100.560 35.920
201409 55.565 100.428 72.910
201412 -35.133 99.070 -46.732
201503 29.168 99.621 38.583
201506 34.182 100.684 44.738
201509 42.407 100.392 55.664
201512 53.556 99.792 70.721
201603 27.211 100.470 35.690
201606 17.638 101.688 22.857
201609 36.928 101.861 47.773
201612 44.584 101.863 57.677
201703 -0.769 102.862 -0.985
201706 42.666 103.349 54.402
201709 -23.737 104.136 -30.037
201712 48.599 104.011 61.572
201803 10.447 105.290 13.075
201806 41.690 106.317 51.673
201809 32.089 106.507 39.702
201812 40.598 105.998 50.471
201903 11.431 107.251 14.045
201906 35.718 108.070 43.553
201909 51.007 108.329 62.047
201912 59.018 108.420 71.732
202003 -4.399 108.902 -5.323
202006 44.336 108.767 53.715
202009 11.518 109.815 13.821
202012 40.693 109.897 48.795
202103 11.205 111.754 13.212
202106 23.777 114.631 27.333
202109 57.400 115.734 65.356
202112 60.559 117.630 67.842
202203 59.783 121.301 64.946
202206 50.164 125.017 52.876
202209 70.708 125.227 74.406
202212 51.708 125.222 54.415
202303 5.226 127.348 5.408
202306 43.319 128.729 44.345
202309 107.488 129.860 109.075
202312 -11.742 129.419 -11.956
202403 35.184 131.776 35.184

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Merck  (UKEX:MRK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Merck's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=4844.00/144.64
=33.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 14.33. And the median was 22.51.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Merck Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (UKEX:MRK) Business Description

Industry
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (UKEX:MRK) Headlines